Stabilized formulation of triamcinolone acetonide
AssigneeThe University of Mississippi
InventorsMichael A. Repka, Hossein Shabany, Angela Sutterer
Life of this patent
Estimating the term…
Abstract
A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.
Claims28
A storage stable therapeutic composition having wet adherent properties comprising a base material, a preservative, about 0.1 wt. % triamcinolone acetonide, and about 2 wt. % lidocaine hydrochloride, the base material comprising from about 3 to 15 wt. % of a water soluble salt of a copolymer of a lower alkyl vinyl ether and maleic acid or anhydride and from about 85 to 97 wt. % of polyethylene glycol;
- wherein the composition is free from butylated hydroxytoluene and free from butylated hydroxyanisole.
A storage stable therapeutic composition having wet adherent properties comprising:
- (i) a base material, a preservative, about 0.01 to about 0.3 wt. % triamcinolone acetonide, and
- (ii) about 0.25 to about 6 wt. % lidocaine hydrochloride,
- the base material comprising from about 3 to 15 wt. % of a water soluble salt of a copolymer of a lower alkyl vinyl ether and maleic acid or anhydride and from about 85 to 97 wt. % of a polyalkylene glycol;
- wherein the composition is free from butylated hydroxytoluene and free from butylated hydroxyanisole.
A composition for the treatment of mouth sores comprising a polyalkylene glycol, a water soluble salt of a copolymer of a lower alkyl vinyl ether and maleic acid or anhydride, lidocaine hydrochloride, triamcinolone acetonide, and a preservative, wherein the composition is free from butylated hydroxytoluene, butylated hydroxyanisole, and EDTA.
A storage stable therapeutic composition housed in a container;
- comprising:
- (i) a base material, about 0.01 to about 0.3 wt. % triamcinolone acetonide, and
- (ii) about 0.25 to about 6 wt. % lidocaine hydrochloride,
- the base material comprising from about 3 to 15 wt. % of a water soluble salt of a copolymer of a lower alkyl vinyl ether and maleic acid or anhydride and from about 85 to 97 wt. % of a polyalkylene glycol;
- wherein said composition is housed in an oxygen impermeable container that allows for the dispensing of said composition.
A storage stable therapeutic composition for the treatment of mouth sores having wet adherent properties comprising:
- (i) a base material, about 0.01 to about 0.3 wt. % triamcinolone acetonide, and
- (ii) about 0.25 to about 6 wt. % lidocaine hydrochloride;
- and
- (iii) a preservative;
- wherein the base material comprising from about 3 to 15 wt. % of a water soluble salt of a copolymer of a lower alkyl vinyl ether and maleic acid or anhydride and from about 85 to 97 wt. % of a polyalkylene glycol;
- and
- wherein the composition is free from butylated hydroxytoluene, butylated hydroxyanisole, and EDTA.
Dependencies are inferred from the claim text.